NCCN Flash Update: NCCN Guidelines and Compendium Updated
Flash Update Sent December 8, 2010
NCCN has published updates to the NCCN Guidelines and the NCCN Drugs & Biologics Compendium (NCCN Compendium™) for Breast Cancer. These NCCN Guidelines are currently available as Version 2.2011.
- Denosumab was added to the Guidelines as an option for the prevention of skeletal-related events in patients with bone metastases with the following footnote: “Denosumab, zoledronic acid, or pamidronate (all with calcium and vitamin D supplementation) should be given (category 1) in addition to chemotherapy or endocrine therapy if bone metastasis present, expected survival 3 months or more, and renal function is adequate. Patients should undergo a dental examination with preventive dentistry prior to initiation of this therapy. The optimal schedule and duration of denosumab, zoledronic acid, or pamidronate are unknown.”
- Eribulin was added to the list of preferred single agents for recurrent or metastatic breast cancer (category 2A).
- The discussion section has been updated to reflect the changes in the algorithm.
NCCN has published updates to the following chapter of the NCCN Compendium™ to reflect updates to the 2011
version of the corresponding NCCN Guidelines:
For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.